

8 Literaturverzeichnis

1. Müller, R. H., Rühl, D., Runge, S., Schulze-Forster, K., Mehnert, W., Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant, *Pharm Res* 14, 458-462 (1997).
2. Müller, R. H., Gohla, S., Dingler, A., Schneppe, T., Large scale production of solid lipid nanoparticles (SLNTM) and nanosuspensions (DissoCubesTM), in: D. Wise (Hrsg.), *Handbook of Pharmaceutical Controlled Release Technology*, Marcel Dekker Inc. New York (im Druck).
3. Zimmermann, E., Feste Lipidnanopartikel (SLN) als kolloidaler Arzneistoffträger für die orale und intravenöse Applikation eines chemisch instabilen Wirkstoffs, Dissertation, Freie Universität Berlin (2001).
4. zur Mühlen, A., Schwarz, C., Mehnert, W., Solid lipid nanoparticles (SLN) for controlled drug delivery - drug release and release mechanism, *Eur J Pharm Biopharm* 45, 149-155 (1998).
5. Westesen, K., Bunjes, H., Koch, M. H. J., Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential, *J Control Rel* 48, 223-236 (1997).
6. Westesen, K., Siekmann, B., Investigation of the gel formation of phospholipid-stabilized solid lipid nanoparticles, *Int J Pharm* 151, 35-45 (1997).
7. Freitas, C., Müller, R. H., Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase, *Eur J Pharm Biopharm* 47, 125-132 (1999).
8. Müller, R. H., Radtke, M., Wissing, S. A., Nanostructured lipid matrices for improved microencapsulation of drugs, *Int J Pharm* 242, 121-128 (2002).
9. Müller, R. H., Mäder, K., Lippacher, A., Jennings, V., Fest-flüssige (halbfeste) Lipidpartikel und Verfahren zur Herstellung hochkonzentrierter Lipidpartikeldispersionen, PCT Anmeldung PCT/EP00/04565 (2000).
10. Müller, R. H., Jennings, V., Zusammensetzung, Herstellung und Verwendung einer Suspension verfestigter, amorpher Öltröpfchen, Deutsche Patentanmeldung 199 38 371.5 (2000).
11. Jennings, V., Thünemann, A. F., Gohla, S. H., Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids, *Int J Pharm* 199(2), 167-177 (2000).

12. Jennings, V., Feste Lipid-Nanopartikel (SLN) als Trägersystem für die dermale Applikation von Retinol: Wirkstoffinkorporation, -freisetzung und Struktur, Dissertation, Freie Universität Berlin (1999).
13. Jennings, V., Schafer-Korting, M., Gohla, S., Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties, *J Control Release* 66(2-3), 115-126 (2000).
14. Müller, R. H., Radtke, M., Wissing, S. A., Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations, *Adv Drug Del Rev* 54 (Suppl. 1), S131-S155 (2002).
15. de Vringer, T., Topical preparation containing a suspension of solid lipid particles, European application EP 0506197 A1 (1992).
16. Lippacher, A., Pharmazeutisch-technologische Charakterisierung von flüssigen und halbfesten SLN Dispersionen für die topische Applikation, Dissertation, Freie Universität Berlin (2000).
17. Lippacher, A., Müller, R. H., Mäder, K., Investigation on the viscoelastic properties of lipid based colloidal drug carriers, *Int J Pharm* 196, 227-230 (2000).
18. Lippacher, A., Müller, R. H., Mäder, K., Production and physical characterisation of semisolid SLN dispersions as drug carrier for topical application, *Proc. 3rd World Meeting on Pharm., Biopharm. and Pharm. Technology*, Berlin, 427-428 (2000).
19. Lippacher, A., Müller, R. H., Mäder, K., Semisolid SLNTM dispersions for topical application: influence of formulation and production parameters on microstructure, *Eur J Pharm Biopharm* 53, 155-160 (2002).
20. Lippacher, A., Müller, R. H., Mäder, K., Liquid and semisolid SLNTM dispersions for topical application: rheological characterization, *Int J Pharm*, (eingereicht).
21. Jennings, V., Gohla, S. H., Encapsulation of retinoids in solid lipid nanoparticles (SLN), *J Microencapsul* 18(2), 149-158. (2001).
22. Dingler, A., Blum, R. P., Niehus, H., Gohla, S., Müller, R. H., Solid lipid nanoparticles (SLNTM/LipopearlsTM) - A pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products, *J Microencapsulation* 16, 751-767 (1999).
23. Wissing, S., Müller, R. H., The influence of solid lipid nanoparticles (SLN) on skin hydration and viscoelasticity - in vivo study, *Eur J Pharm Biopharm*, (eingereicht).
24. Jennings, V., Gysler, A., Schafer-Korting, M., Gohla, S. H., Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin, *Eur J Pharm Biopharm* 49(3), 211-218. (2000).

25. Santos Maia, C., Mehnert, W., Schäfer-Korting, M., Solid lipid nanoparticles as drug carriers for topical glucocorticoids, *Int, J Pharm* 196, 165-167 (2000).
26. de Vringer, T., de Ronde, H. A. G., Preparation and structure of a water-in-oil cream containing lipid nanoparticles, *J Pharm Science* 84, 466-472 (1995).
27. Runge, S. A., Feste Lipid-Nanopartikel (SLN) als kolloidaler Arzneistoffträger für Ciclosporin A, Dissertation, Freie Universität Berlin (1998).
28. Brown, M. D., Gupta, A. K., Ellis, C. N., Rocher, L. L., Voorhees, J. J., Therapy of dermatologic disease with cyclosporin A, *Adv Dermatol* 4, 3-27 (1989).
29. Dingler, A., Feste Lipid-Nanopartikel als kolloidale Wirkstoffträgersysteme zur dermalen Applikation, Dissertation, Freie Universität Berlin (1998).
30. Embil, K., Nacht, S., The micro sponge delivery system (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives, *J Microencapsul* 13(5), 575-588 (1996).
31. Fahr, A., Kissel, T., Mikropartikel und Implantate: Arzneiformen zur parenteralen Applikation, in: R.H. Müller and G.E. Hildebrand (Hrsg.), *Pharmazeutische Technologie: Moderne Arzneiformen*, Wissenschaftliche Verlagsgesellschaft Stuttgart, 187-202 (1997).
32. Ghyczy, M., Arzneimittel mit Phosphatidylcholin und Liposomen: Entwicklung, Bewertung, Perspektiven, in: R.H. Müller and G.E. Hildebrand (Hrsg.), *Pharmazeutische Technologie: Moderne Arzneiformen*, Wissenschaftliche Verlagsgesellschaft Stuttgart, 155-166 (1997).
33. Bangham, A. D., Horne, R. W., Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope, *J Mol Biol* 8, 660-668 (1964).
34. Schreier, H., Bouwstra, J., Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery, *J Control Rel* 30, 1-15 (1994).
35. Theis, H., Göhring, S., Einsatz von Sphingolipiden in Hautpflegeprodukten, *SÖFW* 121(5), 342-348 (1995).
36. Kreuter, J., Nanoparticle-based drug-delivery systems, *J Control Rel* 16, 169-176 (1991).
37. Merodio, M., Arnedo, A., Renedo, M. J., Irache, J. M., Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties, *Eur J Pharm Sci* 12(3), 251-259. (2001).
38. Müller, R. H., Böhm, B. H. L., Nanosuspensions, in: R.H. Müller, S. Benita, and B.H.L. Böhm (Hrsg.), *Emulsions and nanosuspensions for the formulation of poorly soluble drugs*, medpharm Scientific Publishers Stuttgart, 149-174 (1998).

39. Speiser, P., Lipidnanopellets als Trägersystem für Arzneimittel zur peroralen Anwendung, European Patent EP 0167825 (1990).
40. Domb, A. J., Lipospheres for controlled delivery of substances, US Patent US 5,188,837 (1993).
41. Radtke, M., Müller, R. H., Comparison of structural properties of solid lipid nanoparticles (SLNTM) versus other lipid particles, Intern. Symp. Control. Rel. Bioact. Mater. 27, 309-310 (2000).
42. Müller, R. H., Lucks, J. S., Arzneistoffträger aus festen Lipidteilchen, Feste Lipidnanosphären (SLN), European Patent EP 0605497 (1996).
43. Gasco, M. R., Method for producing solid lipid microspheres having a narrow size distribution, US Patent US 5,250,236 (1993).
44. Siekmann, B., Westesen, K., Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions, Eur J Pharm Biopharm 43, 104-109 (1996).
45. Heiati, H., Tawashi, R., Phillips, N. C., Drug retention and stability of solid lipid nanoparticles containing azidothymidine palmitate after autoclaving storage and lyophilization, J Microencapsulation 15, 173-184 (1998).
46. Heiati, H., Tawashi, R., Phillips, N. C., Solid lipid nanoparticles as drug carriers, II. Plasma stability and biodistribution of solid lipid nanoparticles containing the lipophilic prodrug 3'-azido-3'-deoxythymidine palmitate in mice, Int J Pharm 174, 71-80 (1998).
47. Chen, D. B., Yang, T. Z., Lu, W. L., Zhang, Q., In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel, Chemical and pharmaceutical bulletin 49(11), 1444-1447 (2001).
48. Cavalli, R., Bocca, A., Miglietta, A., Caputo, O., Gasco, M. R., Albumin adsorption on stealth and non-stealth solid lipid nanoparticles, STP Pharma Sci 9(183-189), (1999).
49. Yang, S. C., Lu, L. F., Cai, Y., Zhu, J. B., Liang, B. W., Yang, C. Z., Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain, J Control Rel 59, 299-307 (1999).
50. Cavalli, R., Caputo, O., Carlotti, M. E., Trotta, M., Scarnecchia, C., Gasco, M. R., Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles, Int J Pharm 148, 47-54 (1997).
51. Müller, R. H., Dingler, A., Weyhers, H., zur Mühlen, A., Mehnert, W., Solid lipid nanoparticles (SLN) - ein neuartiger Wirkstoff-Carrier für Kosmetika und Pharmazeutika, III. Langzeitstabilität, Gefrier- und Sprühtrocknung, Anwendung in Kosmetika und Pharmazeutika, Pharm Ind 59(7), 614-619 (1997).

52. Freitas, C., Müller, R. H., Spray Drying of Solid Lipid Nanoparticles (SLNTM), *Eur J Pharm Biopharm* 46, 145-151 (1998).
53. Fresta, M., Bucolo, C., Maltese, A., Mangiafico, S., Puglisi, G., Pegylated Solid Lipid Nanospheres as ophthalmic delivery systems of dexamethasone, *Proc. 4th World Meeting on Pharm., Biopharm. and Pharm. Technology*, Florence, 939-940 (2002).
54. Harmia, T., Speiser, P., Kreuter, J., A solid colloidal drug delivery system for the eye: encapsulation of pilocarpine in nanoparticles, *J Microencapsul* 3, 3-12 (1986).
55. Wissing, S. A., SLN als innovatives Formulierungskonzept für pflegende und protektive dermale Zubereitungen, *Dissertation*, Freie Universität Berlin (2002).
56. Gasco, M. R., Solid lipid nanoparticles for drug delivery, *Pharmaceutical Technology Europe* February, 32-42 (2001).
57. Mehnert, W., Mäder, K., Solid lipid nanoparticles - production, characterization and applications, *Adv Drug Del Rev* 47, 165-196 (2001).
58. Müller, R. H., Mehnert, W., Lucks, J. S., Schwarz, C., zur Mühlen, A., Weyhers, H., Freitas, C., Rühl, D., Solid Lipid Nanoparticles (SLN) - An Alternative Colloidal Carrier System for Controlled Drug Delivery, *Eur J Pharm Biopharm* 41(1), 62-69 (1995).
59. Müller, R. H., Mäder, K., Gohla, S., Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art, *Eur J Pharm Biopharm* 50(1), 161-177 (2000).
60. Westesen, K., Novel lipid-based colloidal dispersions as potential drug administration systems - expectations and reality, *Colloid Polym Sci* 278, 608-618 (2000).
61. Mehnert, W., zur Mühlen, A., Dingler, A., Weyhers, H., Müller, R. H., Solid lipid nanoparticles (SLN) - ein neuartiger Wirkstoff-Carrier für Kosmetika und Pharmazeutika, II. Wirkstoffinkorporation, Freisetzung und Sterilisierbarkeit, *Pharm Ind* 59(6), 511-514 (1997).
62. zur Mühlen, A., Mehnert, W., Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles, *Pharmazie* 53, 552 (1998).
63. Bunjes, H., Einflußnahme unterschiedlicher Faktoren auf Struktur und Eigenschaften von Nanopartikeln aus festen Triglyceriden, *Dissertation*, Friedrich-Schiller-Universität Jena (1998).
64. Schwarz, C., Feste Lipid Nanopartikel: Herstellung, Charakterisierung, Arzneistoffinkorporation und - freisetzung, *Dissertation*, Freie Universität Berlin (1995).

65. Wissing, S. A., Müller, R. H., Solid lipid nanoparticles as carriers for sunscreens: in vitro release and in vivo skin penetration, *J Control Rel* 81, 225-233 (2001).
66. zur Mühlen, A., Schwarz, C., Mehnert, W., Müller, R. H., Produktion von 'solid lipid nanoparticles' (SLN) für die kontrollierte Wirkstoffapplikation, *Arch Pharm* 326, 752 (1993).
67. zur Mühlen, A., Feste Lipidnanopartikel mit prolongierter Wirkstoffliberation: Herstellung, Langzeitstabilität, Charakterisierung, Freisetzungsverhalten und -mechanismen, Dissertation, Freie Universität Berlin (1996).
68. Müller, R. H., Schwarz, C., zur Mühlen, A., Mehnert, W., Incorporation of lipophilic drugs and drug release profiles of solid lipid nanoparticles (SLN), *Int. Symp. Control. Release Bioact. Mater.* 21, 146-147 (1994).
69. Siekmann, B., Westesen, K., Thermoanalysis of the recrystallization process of melt-homogenized glyceride nanoparticles, *Colloids and Surfaces B: Biointerfaces* 3, 159-175 (1994).
70. Freitas, C., Feste Lipid-Nanopartikel (SLN): Mechanismen der physikalischen Destabilisierung und Stabilisierung, Dissertation, Freie Universität Berlin (1998).
71. Unruh, T., Westesen, K., Bösecke, P., Lindner, P., Koch, M. H. J., Self-assembly of triglyceride nanocrystals in suspension, *Langmuir* 18, 1796-1800 (2002).
72. Bunjes, H., Westesen, K., Koch, M. H. J., Crystallization tendency and polymorphic transitions in triglyceride nanoparticles, *Int J Pharm* 129, 159-173 (1996).
73. Jennings, V., Mäder, K., Gohla, S. H., Solid lipid nanoparticles (SLN) based on binary mixtures of liquid and solid lipids: a ¹H-NMR study, *Int J Pharm* 205(1-2), 15-21 (2000).
74. Manthei, L., Strukturanalyse von Nanopartikeln, Diplomarbeit, Universität Duisburg - Essen (2003).
75. Jores, K., Mehnert, W., Mäder, K., Physicochemical investigations on solid lipid nanoparticles (SLN) and on oil-loaded solid lipid nanoparticles: a NMR- and ESR-study, *Pharm Res* (akzeptiert).
76. Olbrich, C., Entwicklung optimierter Lipidcarrier und ihre Untersuchung in biologischen Systemen, Dissertation, Freie Universität Berlin (2002).
77. Olbrich, C., Gessner, A., Kayser, O., Müller, R. H., Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate, *J Drug Target* 10(5), 387-396 (2002).

78. Wissing, S. A., Müller, R. H., The influence of the crystallinity of lipid nanoparticles on their occlusive properties, *Int J Pharm* 242(1-2), 377 (2002).
79. Wissing, S., Müller, R. H., Solid lipid nanoparticles (SLN) - a novel carrier for UV-blockers, *Pharmazie* 56, 783-786 (2001).
80. Müller, R. H., Olbrich, C., Neue Adjuvantien in der Impfstofftechnologie, in: O. Kayser and R.H. Müller (Hrsg.), *Pharmazeutische Biotechnologie*, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 278-298 (2000).
81. Olbrich, C., Müller, R. H., Tabatt, K., Kayser, O., Schulze, C., Schade, R., Stable biocompatible adjuvants - a new type of adjuvant based on solid lipid nanoparticles: A Study on cytotoxicity, compatibility and efficacy in chicken, *Atla* 30, 1-15 (2002).
82. Tabatt, K., Pharmazeutisch-biotechnologische Anwendungen von Festen Lipidnanopartikel (SLN): Vakzinadjuvantien und Gentransfervehikel, Dissertation, Freie Universität Berlin (2002).
83. Olbrich, C., Bakowsky, U., Lehr, C.-M., Müller, R. H., Kneuer, C., Cationic Solid Lipid Nanoparticles can efficiently bind and transfect plasmid DNA, *J Control Rel* 77, 345-355 (2001).
84. Schütt, D. H., Kaiser, E., Stamm, I., Kubis, A., Müller, R. H., New Generation of Cosmetic Products Based on Solid Lipid Nanoparticles (Lipopearls™), 2nd World Meeting Pharm., Biopharm. and Pharm. Technology, Paris, 585-586 (1998).
85. Hadgraft, J., Recent developments in topical and transdermal delivery, *Eur J Drug Metab Pharmacokinet* 21(2), 165-173 (1996).
86. Hadgraft, J., Passive enhancement strategies in topical and transdermal drug delivery, *Int J Pharm* 184(1), 1-6 (1999).
87. Moser, K., Kriwet, K., Naik, A., Kalia, Y. N., Guy, R. H., Passive skin penetration enhancement and its quantification in vitro - review article, *Eur J Pharm Biopharm* 52, 103-112 (2001).
88. Megrab, N. A., Williams, A. C., Barry, B. W., Oestradiol permeation through human skin and silastic membrane: effects of propylene glycol and supersaturation, *J Control Rel* 36, 277-294 (1995).
89. Pellett, M. A., Castellano, S., Hadgraft, J., Davis, A. F., The penetration of supersaturated solutions of piroxicam across silicone membranes and human skin in vitro, *J Control Release* 46, 205-214 (1997).
90. Moser, K., Kriwet, K., Froehlich, C., Kalia, Y. N., Guy, R. H., Supersaturation: enhancement of skin penetration and permeation of a lipophilic drug, *Pharm Res* 18(7), 1006-1011 (2001).

91. Moser, K., Kriwet, K., Kalia, Y. N., Guy, R. H., Enhanced skin permeation of a lipophilic drug using supersaturated formulations, *J Control Release* 73(2-3), 245-253 (2001).
92. Moser, K., Kriwet, K., Froehlich, C., Naik, A., Kalia, Y. N., Guy, R. H., Permeation enhancement of a highly lipophilic drug using supersaturated systems, *J Pharm Sci* 90(5), 607-616 (2001).
93. Iervolino, M., Raghavan, S. L., Hadgraft, J., Membrane penetration enhancement of ibuprofen using supersaturation, *Int J Pharm* 198(2), 229-238 (2000).
94. Raghavan, S. L., Trividic, A., Davis, A. F., Hadgraft, J., Effect of cellulose polymers on supersaturation and in vitro membrane transport of hydrocortisone acetate, *Int J Pharm* 193(2), 231-237 (2000).
95. Raghavan, S. L., Kiepfer, B., Davis, A. F., Kazarian, S. G., Hadgraft, J., Membrane transport of hydrocortisone acetate from supersaturated solutions; the role of polymers, *Int J Pharm* 221(1-2), 95-105 (2001).
96. Kemken, J., Ziegler, A., Müller, B. W., Influence of supersaturation on the thermodynamic effect of bupranolol after dermal administration using microemulsions as vehicle, *Pharm Res* 9, 554-558 (1992).
97. Müller, B. W., Topische Mikroemulsionen als neue Wirkstoff-Trägersysteme, in: R.H. Müller and G.E. Hildebrand (Hrsg.), *Pharmazeutische Technologie: Moderne Arzneiformen*, Wissenschaftliche Verlagsgesellschaft Stuttgart, 109-116 (1997).
98. Coldman, M. F., Poulsen, B. J., Higuchi, T., Enhancement of percutaneous absorption by the use of volatile:nonvolatile systems as vehicles, *J Pharm Sci* 58, 1098-1102 (1969).
99. Kondo, S., Yamanaka, D., Sugimoto, I., Enhancement of transdermal delivery by superfluous thermodynamic potential. III. Percutaneous absorption of nifedipine in rats, *J Pharmacobio-Dyn* 10, 743-749 (1987).
100. Chiang, C. M., Flynn, G. L., Weiner, G. J., Szpunar, G. J., Bioavailability assessment of topical delivery systems: effect of vehicle evaporation upon in vitro delivery of minoxidil from solution formulations, *Int J Pharm* 55, 229-236 (1989).
101. FDA, Food additive database, Internet: www.fda.gov (2002).
102. Fiedler, H. P., Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete, Editio Cantor Verlag Aulenhof (1996).
103. Arbeitsgemeinschaft der Firmen Ciba Geigy, Hofmann La Roche und Novartis, Katalog pharmazeutischer Hilfsstoffe, Vertrieb über die Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik Mainz (1974).

104. Beyer, H., Walter, W., Lehrbuch der Organischen Chemie, S. Hirzel Verlag Stuttgart (1991).
105. Budavari, S. (Hrsg.), The Merck Index 12, Merck & Co., Inc., Whitehouse Station New Jersey (1996).
106. Willemaers, V., Stas, I., Pierard-Franchimont, C., Cornil, F., Pierard, G. E., Atopic dermatitis, *Rev Med Liege* 53(2), 67-70. (1998).
107. Bauer, K. H., Fömming, K.-H., Führer, C., Pharmazeutische Technologie, Gustav Fischer Verlag Stuttgart (1997).
108. Marques, E. F., Edlund, H., La Mesa, C., Khan, A., Liquid crystals and phase equilibria binary bile salt-water systems, *Langmuir* 16, 5178-5186 (2000).
109. Brooks, G. J., Advantages of sucrose esters in formulating cosmetic creams and lotions, *Cosmet Toiletries* 95, 73-76 (1980).
110. Kutz, G., Peltner, D., Neuere Emulgatoren im Einsatz, *Pharm Ztg* 24, 35-42 (1999).
111. Penkler, L., Müller, R. H., Runge, S., Ravelli, V., Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation, PCT application PCT/EP99/02892 (1999).
112. Hofner, A. F., Sirolimus, ein neues Immunsuppressivum, *Pharm Ztg* 2, 28-33 (2003).
113. Wasielewski, S., Bewährte und neue Immunsuppressiva bei Organtransplantationen, *DAZ* 7, 34-38 (2001).
114. Pfau, B., Kruse, F. E., Rohrschneider, K., Zorn, M., Fiehn, W., Burk, R. O. W., Völcker, H. E., Vergleich zwischen lokaler und systemischer Applikation von Cyclosporin A auf den Wirkspiegel in Bindehaut, Kammerwasser und Serum, *Ophthalmologie* 92, 833-839 (1995).
115. D'Souza, M., DeSouza, P., Preparation and testing of cyclosporine microsphere and solution formulations in the treatment of polyarthritis in rats, *Drug Development and industrial pharmacy* 24(9), 841-852 (1998).
116. Naeyaert, J. M., Lachapelle, J. M., Degreef, H., de la Brassinne, M., Heenen, M., Lambert, J., Cyclosporine in atopic dermatitis. Review of the literature and outline of a Belgian consensus, *Dermatology* 198, 145-152 (1999).
117. Bos, J. D., Meinardi, M. M., The 500 Dalton rule for the skin penetration of chemical compounds and drugs, *Exp Dermatol* 9(3), 165-169 (2000).
118. Assmann, T., Homey, B., Ruzicka, T., Topical tacrolimus for the treatment of inflammatory skin diseases, *Expert Opin Pharmacother* 2(7), 1167-1175 (2001).

119. Fleischer, A. B., Jr., Treatment of atopic dermatitis: role of tacrolimus ointment as a topical noncorticosteroidal therapy, *J Allergy Clin Immunol* 104(3 Pt 2), S126-130 (1999).
120. Cavanak, T., Galenical compositions, US-Patent Nr. 4,388,307 (1983).
121. Hauer, B., Meinzer, A., Posanski, U., Richter, F., Pharmaceutical compositions comprising cyclosporins, US-Patent Nr. 5,342,625 (1996).
122. Meinzer, A., Müller, E., Vonderscher, J., Perorale Mikroemulsionsformulierung - Sandimmun Optoral / Neoral, in: R.H. Müller and G.E. Hildebrandt (Hrsg.), *Pharmazeutische Technologie: Moderne Arzneiformen*, Wissenschaftliche Verlagsgesellschaft Stuttgart, Vol. 2, 169-177 (1998).
123. Stuhne-Sekalec, L., Stanacev, N. Z., Liposomes as carriers of cyclosporin A, *J Microencapsul* 8(4), 441-446 (1991).
124. Fahr, A., Holz, M., Fricker, G., Liposomal formulations of cyclosporin A: influence of lipid type and dose on pharmacokinetics, *Pharm Res* 12(8), 1189-1198 (1995).
125. Guo, J. X., Ping, Q. N., Wu, T., Transdermal delivery mechanisms of lecithin nanoparticles with cyclosporin A through mice skin, *Yao Xue Xue Bao* 35(10), 782-785 (2000).
126. Floc'h, R., Merle, C., Cyclosporin A formulations as nanoparticles, WO 97/35603 (1997).
127. Chen, X., Young, T. J., Sarkari, M., Williams, R. O., 3rd, Johnston, K. P., Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution, *Int J Pharm* 242(1-2), 3-14 (2002).
128. Molpeceres, J., Chacon, M., Guzman, M., Berges, L., del Rosario Aberturas, M., A polycaprolactone nanoparticle formulation of cyclosporin-A improves the prediction of area under the curve using a limited sampling strategy, *Int J Pharm* 187(1), 101-113 (1999).
129. Ugazio, E., Cavalli, R., Gasco, M. R., Incorporation of cyclosporin A in solid lipid nanoparticles (SLN), *Int J Pharm* 241(2), 341-344 (2002).
130. Zhang, Q., Yie, G., Li, Y., Yang, Q., Nagai, T., Studies on the cyclosporin A loaded stearic acid nanoparticles, *Int J Pharm* 200(2), 153-159 (2000).
131. Chacon, M., Molpeceres, J., Berges, L., Guzman, M., del Rosario Aberturas, M., Stability and freeze-drying of cyclosporine loaded poly(D,L lactide-glycolide) carriers, *Eur J Pharm Sci* 8, 99-107 (1999).
132. Tran, H. S., Malli, D., Chrzanowski, F. A., Puc, M. M., Matthews, M. S., Hewitt, C. W., Site-specific immunosuppression using a new formulation of topical cyclosporine A with polyethylene glycol-8 glyceryl caprylate/caprate, *J Surg Res* 83(2), 136-140 (1999).

133. Duncan, J. I., Payne, S. N., Winfield, A. J., Ormerod, A. D., Thomson, A. W., Enhanced percutaneous absorption of a novel topical cyclosporin A formulation and assessment of its immunosuppressive activity, *Br J Dermatol* 123(5), 631-640 (1990).
134. Komiya, K., Igarashi, R., Takenaga, M., Yanagawa, A., Mizushima, Y., Nishimura, T., Kudo, T., Ando, K., Topical preparations containing cyclosporin, US-Patent US 5,504,068 (1996).
135. Hewitt, C. W., Black, K. S., Combined topical and systemic method of administration of cyclosporine, US-Patent Nr. 4,996,193 (1991).
136. Cavalli, R., Marengo, E., Rodriguez, L., Gasco, M. R., Effect of some experimental factors on the production process of solid lipid nanoparticles, *Eur J Pharm Biopharm* 43(2), 110-115 (1996).
137. Hildebrand, G., Tack, J., Harnisch, S., Method for producing morphologically uniform micro and nanoparticles using micromixers, WO 2000072955 A1 (2000).
138. Jahnke, S., Mit Hochdruck aufgeschlossen, *Process - PharmaTEC* 3, 36-37 (2002).
139. Haas, U., Physik für Pharmazeuten und Mediziner, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart (1998).
140. Siekmann, B., Westesen, K., Submicron-sized parenteral carrier systems based on solid lipids, *Pharm Pharmacol Lett* 1, 123-126 (1992).
141. Müller, R. H., Weyhers, H., zur Mühlen, A., Dingler, A., Mehnert, W., Solid lipid nanoparticles - ein neuartiger Wirkstoff-Carrier für Kosmetika und Pharmazeutika, I. Systemeigenschaften, Herstellung und Scaling-up, *Pharm Ind* 59(5), 423-427 (1997).
142. Müller, R. H., Schuhmann, R., Teilchengrößenmessung in der Laborpraxis, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart (1996).
143. Müller, R. H., Mehnert, W., Particle and surface characterisation methods, medpharm Scientific Publishers Stuttgart (1997).
144. Müller, R. H., Zetapotential und Partikelladung in der Laborpraxis, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart (1996).
145. Bott, S., Hart, H., Charakterisierung kleinster Teilchen mit der neuen PIDS-Technologie - Partikelanalyse, *Chemie Technik* 5, 196-200 (1991).
146. Müller, R. H., Polydispersität und elektrophoretische Beweglichkeit hochdispenser Systeme, Dissertation, Christian-Albrechts-Universität Kiel (1983).
147. Skoda, W., Van den Tempel, M., Crystallization of emulsified triglycerides, *J Colloid Sci* 18, 568-584 (1963).

148. Precht, D., Frede, E., Greiff, R., Molekulanordnungen und Kristallgitterdefekte in Fettgemischen, *Fette, Seifen, Anstrichmittel* 9, 344-352 (1978).
149. Larsson, K., Classification of glyceride crystal forms, *Acta Chem Scand* 20(8), 2255-2260 (1966).
150. Hoerr, C. W., Paulicka, F. R., The role of x-ray diffraction in studies of the crystallography of monoacid saturated triglycerides, *J Am Oil Chem Soc* 45, 793-797 (1968).
151. Hernquist, L., Crystal structures of fats and fatty acids, in: N. Garti and K. Sato (Hrsg.), *Crystallization and polymorphism of fats and fatty acids*, Marcel Dekker Inc. New York und Basel, 97-137 (1988).
152. Thoma, K., Serno, P., Precht, D., Röntgendiffraktometrischer Nachweis der Polymorphie von Hartfett, *Pharm Ind* 45(4), 420-425 (1983).
153. Westesen, K., Siekmann, B., Koch, M. H. J., Investigations of the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction, *Int J Pharm* 93, 189-199 (1993).
154. Lukowski, G., Kasbohm, J., Pfliegel, P., Illing, A., Wulff, H., Crystallographic investigation of cetylpalmitate solid lipid nanoparticles, *Int J Pharm* 196(2), 201-205 (2000).
155. Grunenberg, A., Polymorphie und thermische Analyse pharmazeutischer Wirkstoffe, *Pharmazie in unserer Zeit* 5, 224-231 (1997).
156. Burger, A., DTA und DSC: Grundlagen, Methodik und Anwendung, *Pharmazie in unserer Zeit* 6, 177-189 (1982).
157. Westesen, K., Bunjes, H., Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix?, *Int J Pharm* 115, 129-131 (1995).
158. Unruh, T., Bunjes, H., Westesen, K., Observation of size-dependent melting in lipid nanoparticles, *J Phys Chem B* 103, 10373-10377 (1999).
159. Hunter, R. J., *Foundations of colloid science*, Oxford University press Oxford (1986).
160. Krischner, H., *Einführung in die Röntgenfeinstrukturanalyse*, Vieweg Verlag Braunschweig (1990).
161. Wölfel, E. R., *Theorie und Praxis der Röntgenstrukturanalyse*, Vieweg & Sohn Verlagsgesellschaft mbH Braunschweig (1987).
162. Franz, T. J., Percutaneous absorption. On the relevance of in vitro data, *J Invest dermatol* 67, 190-196 (1975).
163. Hassan, M. M., Al-Yahya, M. A., Cyclosporine, in: K. Florey (Hrsg.), *Analytical profile of drug substances*, Academic Press New York, Vol. 16, 145-206 (1987).

164. Kurihara, K., Murano, M., Cyclosporine formulations of mono or diglyceride fatty acids, US Patent US 4,990,337 (1991).
165. Augustijns, P. F., Brown, S. C., Willard, D. H., Consler, T. G., Annaert, P. P., Hendren, R. W., Bradshaw, T. P., Hydration changes implicated in the remarkable temperature-dependent membrane permeation of Cyclosporine A, *Biochemistry* 39, 7621-7630 (2000).
166. Bunjes, H., Koch, M. H. J., Westesen, K., Effect of particle size on colloidal solid triglycerides, *Langmuir* 16, 5234-5241 (2000).
167. Kodali, D. R., Fahey, D. A., Small, D. M., Structure and polymorphism of saturated monoacid 1,2-diacyl-sn-glycerols, *Biochemistry* 29, 10771-10779 (1990).
168. Siekmann, B., Bunjes, H., Koch, M. H., Westesen, K., Preparation and structural investigations of colloidal dispersions prepared from cubic monoglyceride-water phases, *Int J Pharm* 244(1-2), 33-43 (2002).
169. Spicer, P. T., Hayden, K. L., Lynch, M. L., Ofori-Boateng, A., Burns, J. L., Novel process for producing cubic liquid crystalline nanoparticles (Cubosomes), *Langmuir* 17, 5748-5756 (2001).
170. Lee, J., Kellaway, I. W., In vitro peptide release from liquid crystalline buccal delivery systems, *Int J Pharm* 195, 29-33 (2000).
171. Sallam, A., Khalil, E., Ibrahim, H., Freij, I., Formulation of an oral dosage form utilizing the properties of cubic liquid crystalline phases of glyceryl monooleate, *Eur J Pharm Biopharm* 53, 343-352 (2002).
172. Borné, J., Nylander, T., Khan, A., Microscopy, SAXD, and NMR studies of phase behavior of the monoolein-diolein-water system, *Langmuir* 16, 10044-10054 (2000).
173. Plantenberg, T., Kötz, J., Liquid crystalline polyanion/polycation/water systems, *Polymer* 42, 3523-3532 (2000).
174. Wissing, S. A., Lippacher, A., Müller, R. H., Investigations on the occlusive properties of solid lipid nanoparticles (SLNTM), *International Journal of Cosmetic Sciences* 52, 313-324 (2001).
175. Wolff, T., Burger, C., Ruland, W., Small-angle X-ray scattering study of lamellar microdomains in diblock copolymers in the weak segregation regime, *Macromolecules* 27, 3301-3309 (1994).
176. Schote, U., Ganz, P., Fahr, A., Seelig, J., Interactions of cyclosporines with lipid membranes as studied by solid-state nuclear magnetic resonance spectroscopy and high-sensitivity titration calorimetry, *J Pharm Sci* 91(3), 856-867 (2002).
177. Parikh, I., Mishra, A., Cyclosporin emulsions, US Patent US 5,660,858 (1997).

178. Lowe, N. J., Essential fatty acid deficient hairless mouse: the effects of topical agents on the epidermis, *Br J Dermatol* 97(1), 39-47 (1977).
179. Berbis, P., Hesse, S., Privat, Y., [Essential fatty acids and the skin], *Allerg Immunol (Paris)* 22(6), 225-231 (1990).
180. Freitas, C., Müller, R. H., Effect of light and temperature on zeta potential and physical stability in Solid Lipid Nanoparticle (SLNTM) Dispersions, *Int J Pharm* 168 168, 221-229 (1998).
181. Freitas, C., Müller, R. H., Stability Determination of Solid Lipid Nanoparticles (SLNTM) in Aqueous Dispersion after Addition of Electrolyte, *J Microencapsulation* 16(1), 59-71 (1999).
182. Cooper, E. G., Patel, D. C., Practical considerations for topical drug formulations with and without enhancers, in: D.W. Osborne and A.H. Amann (Hrsg.), *Topical drug delivery formulations*, Marcel Dekker Inc. New York and Basel, 1-12 (1990).